Area of research
Oncology · Public Health, Environmental and Occupational Health
Research interest
Research focused on Blinatumomab and Cytokine release syndrome, with related work in Chimeric antigen receptor, Retrospective cohort study, Cohort. Notable publications include 'Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study', 'Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy', and 'Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report'.
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia
Mediport use as an acceptable standard for CAR T cell infusion
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience
Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study